Remove 2006 Remove Doctors Remove FDA
article thumbnail

SQA Regulatory Surveillance Summary 4 | Monthly Update 2021

SQA

The new regulation, RDC 478/2021 , repeals economic monitoring and reporting processes previously established under RDC 185/2006, and initially reduces the number of medical device types for which economic monitoring will be required. FDA plant inspection and pay $50 million in fines and forfeiture. 10 May 2021.

article thumbnail

Health Provider News

Hall Render

workers to be hit by biotech’s latest layoffs Maryland hospital systems differ over medical waste incinerator’s violations UMMC doctors will decide whether to unionize in a vote next month With $300K, Johns Hopkins team to create drug supply dashboard Maryland Hospital Cleared for $3.25 healthcare workforce finds lack of diversity St.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

CPAP MDL Overinflates Plaintiffs’ Claims

Drug & Device Law

Taking the good doctor first, In re Philips Recalled CPAP, Bi-Level Pap, & Mechanical Ventilator Products Litigation , 2023 WL 7019667 (Sp. CPAP II shrugs off plaintiffs’ repeated allegations that defendants “failed to apprise the FDA” of this or that, with the excuse that plaintiffs don’t really “rely” on them. 341 (2001).

Fraud 52
article thumbnail

Confident Learned Intermediaries Defeat Warning Causation

Drug & Device Law

Further, “both doctors testified that they still prescribe [the drug] for patients with conditions similar to plaintiff’s condition.” The prescriber] provided explicit, uncontroverted testimony that, even when provided with the most current research and FDA mandated warnings, as well as the information found in [defendant’s] updated. . .

FDA 59
article thumbnail

Vaccine Products Liability Claims Preempted

Drug & Device Law

The vaccine’s labeling is approved by the FDA and typically a change is allowed only upon FDA approval. While it mentions marketing and presentations made to doctors, the complaint “does not specifically allege how any of these marketing efforts reached [plaintiff’s] pediatrician.” Albrecht , 139 S.Ct.

Fraud 59
article thumbnail

Lack Of Proximate Cause Evidence Dooms Misrepresentation And Warnings Claims

Drug & Device Law

They also had to have been made between the May 2006 PMA approval and the June 2007 implant, and been relied upon by the implanting surgeon or the plaintiff. But it was consistent with the rate in the approved IFU at the time and plaintiff had no evidence that she or her doctor relied on the undifferentiated rate.

Fraud 59